MedTrace Logo

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

NCT01987232 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-08-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with extensive-stage small-cell lung cancer (ES SCLC).

Conditions

  • Extensive-Stage Small-Cell Lung Cancer

Interventions

DRUG

Carfilzomib

Administered by intravenous infusion.

DRUG

Carboplatin

Administered by intravenous infusion.

DRUG

Etoposide

Administered by intravenous infusion.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-05
Primary Completion
2016-08-31
Completion
2017-05-04

Countries

  • United States
  • Canada
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01987232 on ClinicalTrials.gov